

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
Date of first issue: 26.08.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Halofuginone Formulation

Other means of identification : HALOCUR (A009802)
HALOCUR ORAL SOLUTION FOR TREATMENT OF
CALVES (57163)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification


2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Long-term (chronic) aquatic hazard, Category 3	H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Warning

Hazard statements : H315 Causes skin irritation.

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
 Date of first issue: 26.08.2016

H319 Causes serious eye irritation.
 H412 Harmful to aquatic life with long lasting effects.

Precautionary statements :

Prevention:

P264 Wash skin thoroughly after handling.
 P273 Avoid release to the environment.
 P280 Wear protective gloves/ eye protection/ face protection.

Response:

P332 + P313 If skin irritation occurs: Get medical advice/ attention.
 P337 + P313 If eye irritation persists: Get medical advice/ attention.
 P362 + P364 Take off contaminated clothing and wash it before reuse.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Lactic acid	50-21-5 200-018-0	Skin Corr. 1C; H314 Eye Dam. 1; H318	>= 1 - < 3
Halofuginone	82186-71-8	Acute Tox. 2; H300 Acute Tox. 2; H330 Acute Tox. 1; H310 Skin Irrit. 2; H315 Eye Dam. 1; H318 Skin Sens. 1B; H317 Repr. 2; H361f STOT RE 1; H372 (Blood) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 0,025 - < 0,1

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | | |
|----------------------------|---|--|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention if symptoms occur. |
| In case of skin contact | : | In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|---|
| Risks | : | Causes skin irritation.
Causes serious eye irritation. |
|-------|---|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures

5.1 Extinguishing media

- | | | |
|--------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |

Halofuginone Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023
5.2 08.12.2023 845726-00021 Date of first issue: 26.08.2016

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
 Date of first issue: 26.08.2016

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.
 Avoid inhalation of vapour or mist.
 Do not swallow.
 Do not get in eyes.
 Wash skin thoroughly after handling.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:
 Strong oxidizing agents
 Gases

7.3 Specific end use(s)

- Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Halofuginone	82186-71-8	TWA	5 µg/m ³ (OEB 4)	Internal
	Further information: DSEN, Skin			
		Wipe limit	50 µg/100 cm ²	Internal

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Organic vapour type (A)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance	:	liquid
Colour	:	yellow
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	2,1 - 3
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper	:	No data available

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

flammability limit

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Components:

Lactic acid:

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg Remarks: Based on data from similar materials
Acute inhalation toxicity	:	LC50 (Rat): > 5 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403 Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity Remarks: Based on data from similar materials

Halofuginone:

Acute oral toxicity	:	LD50 (Rat): 30 mg/kg LD50 (Mouse): 5 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): 0,053 mg/l Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): 16 mg/kg

Skin corrosion/irritation

Causes skin irritation.

Components:

Lactic acid:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	Corrosive after 1 to 4 hours of exposure
Remarks	:	Based on data from similar materials

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
Date of first issue: 26.08.2016

Halofuginone:

Species : Rabbit
Result : Skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Lactic acid:**

Species : Chicken eye
Remarks : Based on data from similar materials
Result : Irreversible effects on the eye

Halofuginone:

Result : Severe irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Lactic acid:**

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative
Remarks : Based on data from similar materials

Halofuginone:

Exposure routes : Dermal
Species : Guinea pig
Result : Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:**Lactic acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
Date of first issue: 26.08.2016

Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Halofuginone:

Genotoxicity in vitro

: Test Type: Ames test
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Test Type: Chromosomal aberration
Test system: human lymphoblastoid cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Genotoxicity in vivo

: Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Test Type: Cytogenetic assay
Species: Rat
Application Route: Oral
Result: negative

Test Type: DNA Repair
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative
Remarks : Based on data from similar materials

Halofuginone:

Species : Mouse

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

Application Route	:	Oral
NOAEL	:	0,24 mg/kg body weight
Result	:	negative
Species	:	Rat
Application Route	:	Oral
Exposure time	:	63 weeks
NOAEL	:	0,36 mg/kg body weight
Result	:	negative
Species	:	Rat
Application Route	:	Oral
Exposure time	:	26 Months
NOAEL	:	0,09 - 0,18 mg/kg body weight
Result	:	negative

Reproductive toxicity

Not classified based on available information.

Components:**Lactic acid:**

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Mouse Application Route: Ingestion Result: negative
-------------------------------	---	--

Halofuginone:

Effects on fertility	:	Test Type: Fertility Species: Mouse Application Route: Oral Fertility: NOAEL: 0,126 mg/kg body weight Result: No effects on fertility
		Test Type: Fertility Species: Dog Application Route: Oral Fertility: LOAEL: 0,067 mg/kg body weight Result: Effects on fertility
		Test Type: Three-generation reproduction toxicity study Species: Mouse Application Route: Oral General Toxicity F1: LOAEL: 0,063 mg/kg body weight Symptoms: Reduced body weight Result: No effects on fertility and early embryonic development were detected.
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 0,34 mg/kg body weight Embryo-foetal toxicity: NOAEL: 0,67 mg/kg body weight Result: No embryo-foetal toxicity, No teratogenic effects

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
Date of first issue: 26.08.2016

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 0,025 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 0,076 mg/kg body weight
Result: No embryo-foetal toxicity, No teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:**Halofuginone:**

Target Organs : Blood
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Lactic acid:**

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks
Remarks : Based on data from similar materials

Species : Rat
LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

Halofuginone:

Species : Mouse
NOAEL : 0,07 mg/kg
LOAEL : 0,16 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

Species : Rat
NOAEL : 0,13 mg/kg
LOAEL : 0,88 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

Species	:	Dog
NOAEL	:	0,067 mg/kg
LOAEL	:	0,134 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Blood

Species	:	Dog
NOAEL	:	0,075 mg/kg
LOAEL	:	0,16 mg/kg
Application Route	:	Oral
Exposure time	:	26 Weeks
Target Organs	:	Blood

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Halofuginone:**

General Information	:	No human information is available.
Inhalation	:	Remarks: May cause irritation of respiratory tract.
Skin contact	:	Remarks: May cause skin irritation and/or dermatitis. May cause sensitisation by skin contact. Can be absorbed through skin.
Eye contact	:	Remarks: May irritate eyes.

SECTION 12: Ecological information**12.1 Toxicity****Components:****Lactic acid:**

Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
Date of first issue: 26.08.2016

Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50 : > 10 - 100 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Remarks: Based on data from similar materials

Halofuginone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1,8 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

LC50 (Cyprinus carpio (Carp)): 0,3 mg/l
Exposure time: 72 h
Remarks: Based on data from similar materials

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,12 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,02 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50 (Chlorella pyrenoidosa (algae)): 46 mg/l
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

M-Factor (Acute aquatic toxicity) : 10

M-Factor (Chronic aquatic toxicity) : 10

12.2 Persistence and degradability

Components:

Lactic acid:

Biodegradability : Result: Not readily biodegradable.
Remarks: Based on data from similar materials

Halofuginone:

Biodegradability : Result: Not readily biodegradable.

12.3 Bioaccumulative potential

Components:

Lactic acid:

Partition coefficient: n-octanol/water : log Pow: -0,62

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

Halofuginone:

Partition coefficient: n-octanol/water : log Pow: 1,18

12.4 Mobility in soil

Components:

Halofuginone:

Distribution among environmental compartments : log Koc: 3,87
Method: FDA 3.08

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

Halofuginone Formulation

Version 5.2 Revision Date: 08.12.2023 SDS Number: 845726-00021 Date of last issue: 30.09.2023
Date of first issue: 26.08.2016

IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H300 : Fatal if swallowed.
 H310 : Fatal in contact with skin.
 H314 : Causes severe skin burns and eye damage.
 H315 : Causes skin irritation.
 H317 : May cause an allergic skin reaction.
 H318 : Causes serious eye damage.
 H330 : Fatal if inhaled.
 H361f : Suspected of damaging fertility.
 H372 : Causes damage to organs through prolonged or repeated exposure.
 H400 : Very toxic to aquatic life.
 H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
 Aquatic Acute : Short-term (acute) aquatic hazard
 Aquatic Chronic : Long-term (chronic) aquatic hazard
 Eye Dam. : Serious eye damage
 Repr. : Reproductive toxicity
 Skin Corr. : Skin corrosion
 Skin Irrit. : Skin irritation
 Skin Sens. : Skin sensitisation
 STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	08.12.2023	845726-00021	Date of first issue: 26.08.2016

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Aquatic Chronic 3	H412

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN